BIOSTAR PHARM-B(02563) plans to repurchase company H shares.

BIOSTAR PHARM-B(02563) announced that on May 6, 2026, the board of directors has approved the company to repurchase its H shares from time to time on the open market. However, this can only be done after obtaining approval for foreign exchange remittance from the relevant regulatory authorities of the People's Republic of China, and after necessary revisions to the company's articles of association regarding the share repurchase are approved by the shareholders. At the annual general meeting of shareholders held on August 25, 2025, the directors were granted a general and unconditional authorization to repurchase up to 10% of the total H shares issued as of the date of the 2025 shareholders' annual meeting. The company believes that the share repurchase at the present time can demonstrate the company's confidence in its business outlook and prospects, and ultimately bring benefits to the company and create value for shareholders. The board of directors believes that the company's current financial resources are sufficient to support the share repurchase while maintaining a strong financial position.